Cognition Therapeutics Reports Promising Results in Dementia Drug Trial
Cognition Therapeutics has announced positive outcomes from a phase 2 trial of their drug candidate CT1812 for treating dementia with Lewy bodies, marking a significant step forward in addressing neurodegenerative disorders.
Read the full story





















